Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeutic single domain antibodies. Here, we describe and...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Katherine, Binder, Uli, McDowell, William, Tommasi, Rita, Frigerio, Mark, Darby, William G., Hosking, Chris G., Renaud, Lionel, Machacek, Matthias, Lloyd, Peter, Skerra, Arne, Foley, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748587/
https://www.ncbi.nlm.nih.gov/pubmed/31156041
http://dx.doi.org/10.1080/19420862.2019.1626652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748587/
https://www.ncbi.nlm.nih.gov/pubmed/31156041
http://dx.doi.org/10.1080/19420862.2019.1626652

Ejemplares similares